4893.T
Noile-Immune Biotech Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 147.00
+0.00%Year over year
Reported trailing growth
- Revenue
- -28.6%
- EBITDA
- —
- EBIT
- +25.4%
- EPS
- +17.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +0.0%
- EBITDA
- —
- EPS
- -2.1%
Three-year CAGR
- Revenue
- -87.4%
- EBITDA
- —
- EBIT
- +25.4%
- Net income
- +17.7%
- EPS
- +17.7%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026